- Home
- TYG vs URGN Comparison
TYG vs URGN Comparison
Compare TYG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYG
- URGN
- Stock Information
- Founded
- TYG 2003
- URGN 2004
- Country
- TYG United States
- URGN United States
- Employees
- TYG N/A
- URGN N/A
- Industry
- TYG Investment Managers
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- TYG Finance
- URGN Health Care
- Exchange
- TYG Nasdaq
- URGN Nasdaq
- Market Cap
- TYG 485.3M
- URGN 465.9M
- IPO Year
- TYG N/A
- URGN 2017
- Fundamental
- Price
- TYG $43.26
- URGN $11.20
- Analyst Decision
- TYG
- URGN Strong Buy
- Analyst Count
- TYG 0
- URGN 6
- Target Price
- TYG N/A
- URGN $40.75
- AVG Volume (30 Days)
- TYG 97.3K
- URGN 415.3K
- Earning Date
- TYG 01-01-0001
- URGN 03-10-2025
- Dividend Yield
- TYG 8.68%
- URGN N/A
- EPS Growth
- TYG N/A
- URGN N/A
- EPS
- TYG 19.59
- URGN N/A
- Revenue
- TYG $13,675,460.00
- URGN $90,398,000.00
- Revenue This Year
- TYG N/A
- URGN $43.60
- Revenue Next Year
- TYG N/A
- URGN $103.77
- P/E Ratio
- TYG $2.21
- URGN N/A
- Revenue Growth
- TYG N/A
- URGN 9.29
- 52 Week Low
- TYG $29.54
- URGN $9.03
- 52 Week High
- TYG $48.76
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- TYG 48.67
- URGN 53.20
- Support Level
- TYG $43.38
- URGN $11.12
- Resistance Level
- TYG $44.50
- URGN $11.91
- Average True Range (ATR)
- TYG 0.93
- URGN 0.65
- MACD
- TYG 0.20
- URGN 0.02
- Stochastic Oscillator
- TYG 72.04
- URGN 61.51
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.